MoonLake Immunotherapeutics MLTX
12.04
(0.08)
(0.66%)
as of 25 Sep
- Market cap
- $1.0B
- P/E
- 0.0×
Follow MLTX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 12.93 | 0.46 | 9.98 | 51.59 | 21.11 | 9.27 |
Net Debt/EBITDA |
— | 12.08 | (1.52) | 1.11 | 9.51 | 3.16 | 1.32 |
Debt/Assets |
0.00% | 0.05% | 154.92% | 0.37% | 0.00% | 0.00% | 17.46% |
Debt/Equity |
— | (0.02) | (1.29) | 0.00 | 0.00 | 0.00 | 0.24 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 3.49 | 0.13 | 1.12 | 1.19 | 0.98 | 0.86 |
Capex/Depreciation |
— | — | 0.00 | (0.10) | (0.77) | (0.38) | (0.01) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (0.08%) | 63.83% | (175.19%) | (12.37%) | (24.60%) | (59.99%) | |
| — | (0.16%) | (7.19%) | (115.51%) | (11.94%) | (23.68%) | (50.38%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (1,362.45%) | (1,667.26%) | 0.00% |
Return on Tangible Assets |
— | (6.08%) | 39.83% | (72.54%) | (7.14%) | (26.28%) | (60.33%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.11) | (0.21) | (1.90) | (0.88) | (1.86) | (3.04) |
Cash per Share |
— | 0.46 | 2.80 | 2.46 | 10.40 | 7.13 | 6.11 |
Shareholders Equity per Share |
— | (0.86) | (4.05) | 2.34 | 10.45 | 7.21 | 4.72 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.86) | (4.05) | 2.34 | 10.45 | 7.21 | 4.72 |
Free Cash Flow |
— | (0.32) | (0.61) | (55.91) | (43.06) | (117.11) | (196.04) |
Working Capital |
— | 1.49 | (11.45) | 68.85 | 504.20 | 451.83 | 376.22 |
Capital Expenditures |
— | — | (0.05) | (0.02) | (0.28) | (0.52) | (0.03) |
Net Current Asset Value |
— | (117.53) | (11.69) | 68.43 | 501.12 | 449.75 | 301.74 |
| Other line items | |||||||
Quick Ratio |
— | 10.67 | 0.39 | 9.44 | 51.38 | 20.07 | 8.77 |
Depreciation/Fixed assets |
— | — | 0.11 | 3.34 | 1.15 | 1.92 | 4.53 |
Cash ROIC |
— | 28.22% | (5.76%) | (39.63%) | (4.21%) | (13.01%) | (25.45%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.11) | (0.21) | (1.90) | (0.87) | (1.85) | (3.04) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | 0.00 |
Average Receivables |
— | — | — | 0.18 | 0.64 | 1.95 | 3.86 |
Average Payables |
— | — | 0.82 | 0.91 | 1.05 | 5.41 | 19.27 |
Average Assets |
— | 58.32 | 63.16 | 43.26 | 301.69 | 502.24 | 451.18 |
Average Common Equity |
— | 110.21 | (7.12) | 28.52 | 291.13 | 483.44 | 378.94 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates